Precision Medicine

Deploy disruptive innovation to develop precision-targeted therapies. We help you identify predictive biomarkers, develop and deploy diagnostic tests, and engage the most appropriate patient populations to demonstrate the safety and efficacy of your therapeutic products.

Accelerate the path to precision medicine

Experience and insights to help you to avoid obstacles and optimize your path to developing new personalized medicines and companion diagnostics

  • Through Q2 Solutions' Oncology Center of Excellence, our experts in biomarker discovery are providing a better understanding of therapeutic targets, molecular signaling, drug biology and patient response
  • Q2 Solutions' bioinformatics experts and scientists have published over 150 peer-reviewed articles in leading scientific journals since 2001 and have taken major roles in the FDA-led MAQC and SEQC projects
  • Adopt innovative new strategies for patient selection. We've developed dramatically more efficient means of enrolling rare, biomarker-defined patients - leveraging next-generation sequencing and our established site relationships
  • Q2 Solutions helped develop diagnostics for many of the biomarkers used today, including CTLA4, PD-1/PD-L1, BCR-Abl, ALK, BRAF, C-KIT, EGFR, KRAS and HER2

Extensive laboratory services across the development lifecycle

Our precision medicine laboratory services span the development lifecycle. We can begin with biomarker identification programs in early development and then progressively develop candidate biomarkers into research-appropriate tests and market-ready companion diagnostics

Early clinical development Recruitment and enrollment Post-approval
Genomics can help to identify patients who may respond most appropriately to a particular therapeutic. These results can help stratify populations in later phase trials. Enriching study populations using predictive biomarkers may improve efficacy signals while reducing drug development costs and timelines. Genomic insight can be used to optimize treatment decisions and ensure that the right drug is used to treat the right patient at the right time.

End-to-end integration



Biomarker Roadmap to Success

Develop a biomarker roadmap for a successful strategy in developing targeted therapies

The importance of bioinformatics in immuno-oncology development

Big data solutions and bioinformatics services for genomic insights

Significant Developments, Trends and Approaches in Next Generation Flow Cytometry

Q&A with Mark Edinger

Companion Diagnostic Development: Current trends and recommendations

Lab of the Future

How the lab of the future provides scientific, technological, and operational expertise to improve outcomes

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Anatomic Pathology brochure

Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services

Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet your clinical trial needs

Q2 Solutions Comprehensive Cancer Panel

Targeted sequencing assay

Precision Medicine – Leveraging Genomics in Clinical Research

Part one

Precision Medicine: Applying Genomics Outside of Oncology

Part two

Planning and implementing biomarker testing for immuno-oncology trials

Exploring the challenges with the diverse clinical biomarker requirements

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Read More